

Arjun V Balar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9071949/arjun-v-balar-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20
papers

4,565
citations

9
h-index

21
g-index

21
ext. papers

5,790
ext. citations

8.8
avg, IF

4.68
L-index

#	Paper	IF	Citations
20	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101485 ^{2,2}		2
19	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	2
18	Prescreening to Increase Therapeutic Oncology Trial Enrollment at the Largest Public Hospital in the United States. <i>JCO Oncology Practice</i> , 2021 , OP2100629	2.3	0
17	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer 2021 , 9,		2
16	PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. <i>Future Oncology</i> , 2021 , 17, 137-149	3.6	5
15	Lung Metastases Versus Second Primary Lung Cancers in Patients with Primary Urothelial Carcinoma of the Bladder: A National Population-Based Assessment. <i>Bladder Cancer</i> , 2021 , 7, 347-354	1	0
14	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. <i>Oncology</i> , 2020 , 98, 905-912	3.6	5
13	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020 , 78, 907-915	10.2	9
12	Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2019 , 11, 1756287219839285	3.2	7
11	High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2019 , 129, 146-152	1.6	17
10	Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2019 , 21, 24	6.3	13
9	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2592-2600	2.2	226
8	Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Oncologist</i> , 2019 , 24, 688-690	5.7	10
7	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1949-1956	2.2	72
6	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy 2018 , 6, 97		9
5	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017 , 389, 67-76	4 ⁰	1171
4	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1483-1492	21.7	688

3	Atezolizumab in invasive and metastatic urothelial carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 1295-1301	3.8	8
2	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016 , 387, 1909-20	40	2308
1	Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?. <i>Cancer</i> , 2015 , 121, 179-87	6.4	11